latest news stock values companies glp-1 obesity cardiometabolic A new study conducted by leading researchers across the United States suggests GLP-1s could have a much greater impact beyond Obesity market sales potential tightens

For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should patients who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2

GLP-1 receptor agonists have been studied in clinical trials and have shown significant weight loss benefits for certain patients when combined with diet and exercise

More research is needed to determine the best approach to monitoring and managing these patients once the medication is discontinued. According to Maya and colleagues, current evidence on links between GLP-1s and pregnancy complications remain limited, conflicting and subject to residual confounding by indication or selection and recall bias. They added that if gestational weight gain is a result of GLP-1 discontinuation before or early during pregnancy, negative outcomes for the parent-child dyad could result. In the retrospective analysis, the researchers assessed outcomes among 149,790 singleton pregnancies delivered between June 1, 2016, and March 31, 2025

In the second trial, the patients had the same characteristics but were already using PAP therapy

10.1016/j.bbi.2020.03.014 82

(PubMed) Walker JG, Mackinnon AJ, Batterham P, et al